Impotence Medications

Mean retinal venous diameters at baseline, 30, 90, 180 and 300 min for sildenafil and placebo treatments are shown in (Table 1, Fig. 2). An analysis of variance (ANOVA) comparing the effects of sildenafil citrate and placebo on retinal veins diameters showed a significant interaction between time and treatment (P ¼ 0.03), therefore, comparisons of both treatments at each time point were performed.

In comparison to placebo, sildenafil citrate caused a statistically significant vasodilatation of major retinal veins at 90 min (P ¼ 0.004), 180 min (P < 0.0001) and 300 min (P < 0.0001). Compared with the mean of placebo treatment, the mean venous diameter after sildenafil citrate treatment was 4.7% larger at 90 min, 5.5% larger at 180 min, and 5.8% larger at 300 min. There was no statistically significant difference between placebo and sildenafil at 30 min (P ¼ 0.14).

Because our previous study (Metelitsina et al., 2005) had demonstrated a statistically significant decrease in BPm of 15.2% (P ¼ 0.006) and PP of 22.3% (P ¼ 0.006) at 30 min after administration of sildenafil citrate, we investigated whether changes in BPm and PP are associated with an increase in venous diameter after sildenafil treatment. Our analysis, however, showed no statistically significant association between changes in retinal vein diameters and changes in BPm (P ¼ 0.07) or PP (P ¼ 0.25). Also no statistically significant association between changes in retinal vein diameter and changes in IOP (P ¼ 0.67) after sildenafil were detected .